What are extrapyramidal symptoms (EPS) associated with risperidone (Risperdal)?

Extrapyramidal Symptoms (EPS) from Risperdal

EPS from risperidone (Risperdal) are involuntary movement disorders caused by dopamine receptor blockade, and among atypical antipsychotics, risperidone carries the highest risk for these neurological side effects. 1

Types of EPS Associated with Risperidone

Risperidone can cause both acute and chronic extrapyramidal symptoms:

Acute EPS (occur early in treatment):

1. Dystonia - Sudden, involuntary muscle spasms affecting:

• Neck muscles (torticollis)
• Eyes (oculogyric crisis - eyes rolling upward)
• Torso and limbs
• Larynx (life-threatening if causes airway compromise) 1

Risk factors include young age, male gender, and higher doses. These respond well to anticholinergic medications (e.g., benztropine, diphenhydramine). 1

2. Drug-Induced Parkinsonism - Mimics Parkinson's disease with:

• Bradykinesia (slowed movements)
• Tremors
• Muscle rigidity 1

Can be difficult to distinguish from negative symptoms of schizophrenia itself. Treated with anticholinergics or amantadine. 1

3. Akathisia - Severe inner restlessness manifesting as:

• Inability to sit still
• Pacing
• Physical agitation 1

This is frequently misinterpreted as psychotic agitation or anxiety and is a major cause of medication non-adherence. Treatment is challenging; dose reduction is preferred when clinically feasible. Beta-blockers and benzodiazepines may help, though antiparkinsonian agents are inconsistently effective. 1

Chronic EPS (occur with long-term use):

4. Tardive Dyskinesia (TD) - Potentially irreversible involuntary movements:

• Choreiform or athetoid movements primarily affecting the mouth, tongue, and face (lip smacking, tongue protrusion, chewing movements)
• Can affect any body part
• May persist even after discontinuing the medication 1

Cases of TD have been reported in both adults and teenagers taking risperidone. 1 Even low doses (2 mg) can cause TD, though this is less common. 2

Risperidone's EPS Risk Profile

Among atypical antipsychotics, risperidone has the highest propensity to cause EPS, though still lower than traditional antipsychotics like haloperidol. 1 This dose-dependent relationship is critical:

• 2-4 mg/day: EPS risk similar to placebo 3, 4, 5
• 6 mg/day: Minimal EPS, optimal efficacy 3
• >8 mg/day: Significantly increased EPS risk 3, 4

In comparative studies, risperidone produced intermediate EPS levels between clozapine (lowest) and conventional antipsychotics (highest). 6 Recent meta-analysis in children and adolescents found risperidone had a 2.84-fold increased risk of EPS compared to placebo. 7

Risk Factors and Clinical Considerations

Children and adolescents are at higher risk for EPS than adults when taking antipsychotics. 1 Additional risk factors include:

• Female sex (associated with increased EPS risk) 8, 7
• Genetic factors (ABCC2 TT genotype increases risk 5.46-fold) 8
• Longer illness duration 8
• Pre-existing baseline EPS 3
• Concomitant valproate therapy (increases paliperidone levels, risperidone's active metabolite) 9

Monitoring and Management

Assessment for dyskinesias should occur at least every 3-6 months using standardized scales like the Abnormal Involuntary Movement Scale. 1

Management approach:

1. For acute dystonia: Immediate anticholinergic or antihistaminic medication 1

2. For akathisia: Dose reduction if clinically feasible; consider beta-blockers or benzodiazepines 1

3. For drug-induced parkinsonism: Anticholinergics, amantadine, or dose reduction 1

4. For tardive dyskinesia:

   • Continue current dose only if patient is in full remission and dose change would risk relapse
   • Otherwise, lower the dose or switch to another atypical antipsychotic (preferably one with lower EPS risk like quetiapine or clozapine) 1

Prophylactic antiparkinsonian agents may be considered in patients at high risk for acute dystonias or with prior dystonic reactions, particularly those with compliance concerns. 1 However, the need should be reevaluated after the acute phase, as many patients no longer require them during maintenance therapy. 1

Overdose Considerations

In risperidone overdose, EPS are among the most common manifestations, along with drowsiness, sedation, tachycardia, and hypotension. 10 Severe EPS in overdose should be treated with anticholinergic medication. 10